Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib

Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura

(2013) Marshall A. Mazepa et al.   BRITISH JOURNAL OF HAEMATOLOGY

Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib

(2013) Tessa van Balen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research

(2013) Ravi Sarode et al.   JOURNAL OF CLINICAL APHERESIS

ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura

(2013) Jake Shortt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Depletion by Bortezomib through Blocking of Antigen Presentation

(2013) Se Jin Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

How I treat patients with thrombotic thrombocytopenic purpura: 2010

(2010) J. N. George   BLOOD